The ability to achieve inhibition of the CAFs activity or apoptosis through the use of CAFs-associated therapeutic targets (HSD17B2, HOPX) or the ability to directly target inhibition of ACTA2+ CAV1+ CAFs, FN1+ FAP+ CAFs, myCAFs and iCAFs could lead to dramatic advances in PCa therapy. The gene discussed is ACTA2; the disease is posterior cortical atrophy.